EOS imaging Obtains Marketing Approval in South Korea


EOS imaging Obtains Marketing Approval in South Korea

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today announced that the Company has received approval from the Korean Food and Drug Administration (KFDA) to market the EOS® system in South Korea, further expanding the Company’s commercial opportunities in the fast growing Asia Pacific market. The Company has now obtained authorization to market its technology in 34 countries.

Approval to market the EOS system in South Korea follows similar regional authorizations in Japan and Taiwan and represents a significant milestone as the region continues to adopt EOS’ technology for orthopaedic imaging. The KFDA approval will enable the Company to continue expanding its presence in the Asia Pacific medical imaging market, which is predicted to see the highest growth globally during the next 5 years.

To develop the Korean market, EOS has established a distribution partnership with DK Medical Solutions (DKMS), a company established in 1986 and specialized in the import and sales of high end medical equipment, in particular imaging equipment.

Marie Meynadier, CEO of EOS imaging, comments on this new authorization: “”

EOS imaging designs, develops, and markets EOS® and associated solutions, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market in 34 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

, 2013-2019, Transparency Market Research